ClinicalTrials.gg
CompletedNCT03325257Post-ATUUpdated Sep 14, 2021

Post-ATU Study of Nivolumab

An observational study in Melanoma, sponsored by Nantes University Hospital. Completed at 17 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-14.

Sponsored by Nantes University Hospital · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
350
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Melanoma by Nantes University Hospital — 3 open to participants now, 3 under way, none of them phase 3. Melanoma · Nantes University Hospital.

Started
2017
with 1 other
Observational
5 of 13
3 open now
Registered
8th of 13
by date

Among the 13 studies in Melanoma by Nantes University Hospital, this one is one of 2 that started in 2017, is one of 5 observational ones, and was the 8th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

3 of the 13 studies in Melanoma by Nantes University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Melanoma by Nantes University Hospital, or all of them as a file.
02

Study summary

Nivolumab obtained European Marketing authorization in June 2015. Before this date, a Temporary Authorization for Use (ATU) Program in France for nivolumab was set up between September 2014 and August 2015. This program enrolled approximately 600 melanoma patients (unresectable or metastatic).

It appears relevant to conduct a study on patients treated during the ATU to assess thoroughly patient characteristics, efficacy, safety, and patterns of use of nivolumab in real-life conditions.

Read the detailed description

In order to reach goals of this study, collaboration had been established between BMS and the RIC-Mel network (network for Research and Clinical Investigational Research on Melanoma) (NCT03315468).

The RIC-Mel network has set up a national database in order to reference the active file of melanoma patients in France. The RIC-Mel database, supported by Nantes University Hospital, had been approved by French authorities (CCTIRS and CNIL). The RIC-Mel network is coordinated by Pr B. DRENO (Nantes University Hospital) and Pr C. LEBBE (Saint-Louis Hospital, AP-HP, Paris). Nowadays, 49 centres located all over the country are participating, with more than 19,000 melanoma patients included in the database. The RIC-Mel database is referred as one of the privileged access to any research program on melanoma by the Cancerology Group (GCC) of the French Society of Dermatology .

Based on this, BMS and the RIC-Mel network had established a partnership to set up a study in order to estimate the overall survival of melanoma patients treated by Nivolumab during the French ATU program.

Data are collected in the RIC-Mel database by participating centres. Information of centres, follow-up of activity, data reviewing and extractions are realized by the RIC-Mel network. Data analysis is performed by BMS following a developed statistical protocol.

Patients included in the study were patients with unresectable or advanced metastatic melanoma, which received at least one of Nivolumab, dispensed during the French ATU program.

03

Conditions studied

  • Melanoma

Browse trials for

Keywords

  • Unresectable melanoma
  • metastatic melanoma
  • Immunotherapy
  • Nivolumab
  • Temporary Auhorization for Use (ATU)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with unresectable or melanoma cared in participating sites,
  • Patients included in French nivolumab ATU program,
  • Patients treated by at least one perfusion of nivolumab,
  • Patients agreed to participate to the study.

Exclusion criteria

Exclusion Criteria:

  • Patients with unresectable or melanoma not included in French nivolumab ATU program,
  • Patients having initiated Nivolumab after the 31th December 2015,
  • Patients disagreed to participate.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
350 participants (actual)
Patient registry
No

Interventions

  • OtherRoutine care

    This study is an observational one - there is no change to the routine care. Patients received the Nivolumab independently of the study. Only data will be collected during this project.

This study also gives Nivolumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Overall Survival of patients included in the study thanks to subgroups of interest

    Overall survival is defined as the time from index date (initiation of Nivolumab) until date of death due to any cause. Overall survival will be censored on the last date a subject was known to be alive. Estimates of survival rates will be realized for 1-year and 2-year survival. Median time will also be calculated. Subgroups of interest are described in the description of the first Secondary Outcome Measure. Safety Issue: No

    Time frame: 2 years

Secondary outcomes

  1. Distribution of melanoma patients included in the study in all subgroups of interest thanks to their clinical features at the time of treatment initiation

    Subgroups of interest, based on information collected in medical records, were : * ECOG performance status (PF). ECOG PF is attempted to quantify cancer patients' general well-being and activities of daily life. The classifications were 0, 1 or ≥2. * LDH level. This level is considered as a prognostic factor: higher the LDH level, the worst the prognosis. The classifications were ≤Upper Limit of Normal (ULN), \>ULN, \>2 ULN or N/R (Unknown). * History of brain metastasis. These metastases are considered as one of the most difficult-to-treat complications of melanoma. The classifications were No or Yes. * Line of therapy. The classifications were 0, 1, 2 or \>2. * BRAF status. BRAF is a proto-oncogene. Melanoma patients with BRAF mutation are eligible to targeted therapy.The classifications were Yes (mutated), No (wild-type) and Unknown (no research). * Number of metastatic sites. Safety Issue: No

    Time frame: Day 1

  2. Proportion of melanoma patients included in the study categorized by genders overall and by subgroups of interest

    Distribution of females and males. This analyse will be performed for all the study population and by subgroups of interest (as defined in the primary Outcome Measure).Safety Issue: No

    Time frame: Day 1

  3. Distribution of age of melanoma patients included in the study overall and by subgroups of interest

    Age of patients is the age at the start of Nivolumab treatment Safety Issue: No

    Time frame: Day 1

  4. Description of Nivolumab treatment of melanoma patients included in the study

    Average and median of Nivolumab treatment duration and infusion number will be assessed. Median time to discontinuation, whatever the reason and median time to discontinuation of dose related to adverse events. Distribution of reasons for discontinuation. Safety Issue: No

    Time frame: 2 years

  5. Incidence of select grade 3, 4 and 5 adverse events (AE) in melanoma patients included in the study and related to Nivolumab treatment

    An AE is defined as any undesirable experience or manifestation associated with the use of a medical product in a patient. AEs are categorized by grades, which refer to severity : Grade 3 - Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self-care activities of daily living, Grade 4 - Life-threatening consequences, urgent intervention indicated, Grade 5 - Death related to AE. Proportion of patients with at least one or more select AE, distribution, average and median time of AE occurrence, duration and evolution of AEs as well as description of action on Nivolumab treatment will also be assessed. Safety Issue: Yes

    Time frame: 2 years

  6. Progression-free survival of melanoma patients included in the study

    Progression-free survival is defined as the time since Nivolumab initiation to either the first disease progression date or at last known tumour assessment date, or death due to any cause, whichever occurs first. Safety Issue: No

    Time frame: 2 years

  7. Objective response rate of melanoma patients included in the study

    Objective response rate as the number of subjects with a best objective response of either a partial response of a complete response. Objective response rate is the proportion of patients with an objective response. Safety Issue: No

    Time frame: 2 years

07

Study locations

17 sites
  • AP-HP Hôpital Ambroise Paré
    Paris, Boulogne Billancourt 992100, France
  • CHU de Grenoble
    Grenoble, La Tronche 38700, France
  • Chu Amiens
    Amiens, 80408, France
  • Hopital St andré-CHU DE Bordeaux
    Bordeaux, 33000, France
  • Chu Clermont-Ferrand
    Clermont-Ferrand, 63000, France
  • Chu Dijon
    Dijon, 21000, France
  • CH du Mans
    Le Mans, 72000, France
  • Chru Lille
    Lille, 59000, France
  • Centre Léon Bérard de Lyon
    Lyon, 69008, France
  • Hospices Civils de Lyon: Lyon Sud
    Lyon, 69229, France
  • Hôpitaux de Marseille
    Marseille, 13000, France
  • CHU NICE
    Nice, 06000, France
  • CH de PAU
    Pau, 64000, France
  • CHU de Rouen
    Rouen, 76038, France
  • Chu Toulouse
    Toulouse, 31000, France
  • Ch Valence
    Valence, 26000, France
  • Institut Gustave Roussy
    Villejuif, 94800, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Sep 2018, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2017
First posted
Oct 30, 2017
StartActual
Mar 9, 2017
Primary completionActual
Sep 6, 2018
CompletionActual
Mar 1, 2019
Last update
Sep 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03325257
Responsible party
Sponsor
First posted
Oct 30, 2017
Start date
Mar 9, 2017
Primary completion
Sep 6, 2018
Completion
Mar 1, 2019
Last update
Sep 14, 2021

Study contacts

Brigitte DRENO, PU-PH
principal investigator · Nantes University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion